Redeye updates its estimates ahead of Arise’s Q2 report, which is due on 17 July.
IRLAB continued to progress its pipeline in Q224 and met key milestones, such as the clinical entry ...
Redeye raised its Base Case and 2025 forecasts for Transtema following the recently announced large ...
Redeye returns following IRLAB's Q2 report and recent clinical progress.
Det höga ränteläget fortsätter att påverka förvaltningsresultatet negativt, men väntas förbättras i ...
Redeye sees that the sales beat and updated sales growth target for 2024e will excite the market.
Q-linea has reduced the OPEX by SEK 50m annually, suggesting a reduced OPEX run-rate to SEK 40-45m.
- We cut '24e-'26e ARR by 2-3% on continued macro weakness - Still awaiting a return in B2C business...
- We cut '25e-'26e EBIT by 2%... - ...and still expect no organic growth in '24e - Trading at NTM EV...
Inför rapporten för det andra kvartalet som presenteras på fredag räknar Analysguiden med en tillväx...
Redeye provides an update on Circio and a new base case after the rights issue.
Redeye provides a research update following the Q3 report recently published by Newbury.
EU-lagen CRMA (European Critical Raw Materials Act) har blivit godkänd och gäller från och med mars ...
- Started IRL757 clin. development activities in Q2 - Looking for a mesdopetam Ph 3 partner - Webcas...
Lipigon has received a milestone payment of USD1m from Leaderna for the approval of a phase I study ...
Det höga ränteläget fortsätter att påverka förvaltningsresultatet negativt, som sjönk med 6% på årsb...
Redeye briefly comments on Enviro’s recent follow-up order for 500 tons of TPO from a leading Europe...
Finnair reports Q2 results on Jul 19. The market still looks stable, however there have been some es...
Redeye maintains a positive outlook on Nanologica following its Q2 report.
Redeye comments on Invisio ahead of its Q2-results (due 19 July) where we expect strong growth drive...